Pharmacogenetics has revolutionized the way in which drug metabolism was looked upon in the pre-genomic era. Today with the advent of genomics it is possible to genotype an individual. The genetic differences, which determine the disposition of a given drug in an individual, ultimately give differences in drug response. Genotyping and phenotyping tests to predict dose requirement are now increasingly introduced during preclinical and clinical studies of new drugs. However, the hypothesis for the genotype and the phenotype correlation has to be established. Once this correlation will be established and technology to genotype advances enough to give predictive values over 90%, pharmacogenetics will enter the clinics. Pharmacogenetics will help to tailor the drug type and its dosage according to the individual's genotype. It will help to minimize adverse drug reactions as well as cases of nonresponders to the drug therapy. In addition, this will provide better understanding of pharmacogenetic variations both within as well as among major populations/groups of the world.
Our understandings of development of diseases have us to obtain in-depth knowledge of the cause of disease, improved from gross anatomical or metabolic symptoms to drug targeting and drug disposition. Genomics involves much finer resolution at the level of cell and molecules.
the systemic identification of all human genes and gene This is in post-genomic era, unlike in pre-genomic era, products, the study of human genetic variations, the diseases were described at a gross pathological level combined with changes in gene and protein expression and the molecular mechanisms involved in the over time. Genomics is revolutionizing the study of development of diseases remained less known leading to disease processes along with the development and the concept of a uniform disease. Similarly patients were rational use of the drugs. also considered homogenous in their response to drugs, leading to adaptation of universal therapeutic strategies.
PHARMACOGENETICS
Today the scenario has changed. The 3.2 billion letter nucleotide base-pair sequence of the human genome is
The origin and development of pharmacogenetics is now available as a fundamental resource for scientific traced to the early hint by Garrod 3 , Haldane 4 , and later and medical discovery on many fronts 1, 2 . Now the by Williams 5 . The concept was delineated by Motulsky 6 mechanism of a disease and the drug response are being looked upon from the molecular etiology of disease development and drug disposition. In post-genomic era, we are in a position to develop molecular pathological description revealing heterogeneity in disease development as well as drug disposition. www.ijpsonline.com
Pharmacogenetics is the study of the linkage between an individual's genotype with individual's response to a foreign compound. Thus it deals with inherited variations responsible for variable drug effects. It offers the premise of explaining how the individual's make-up of genes determines drug efficacy and toxicity.
Pharmacogenetics had its beginnings about 40 years ago when researchers realized that some adverse reactions were caused by genetically determined variations in enzyme activity 6, 11 . For example, prolonged muscle 12, 13 . Similarly, inherited changes
Cyclooxygenase-2 in a patient's ability to acetylate isoniazid were found to
be the cause of the peripheral neuropathy, which was due to this drug 14, 15 . too high" and "not too low" to avoid toxicity and increase efficacy. Dealing with diversity in drug effects is
The relation between dose and blood concentration of a major problem in clinical medicine and in drug pharmacologically active drug can be altered by the development 10 .
differences in metabolism among individuals. 
REACTIONS (ADRs)
after being approved by the FDA (Table 2) 20-27
GENOME AND GENETIC VARIABILITY
It is a lesser-known fact that for a drug to be approved by the Food and Drug Administration (US), it has to show efficacy only in one third of the population. It is very The study of the genome supports the fundamental unity Table 1 18 .
An ideal drug is one that effectively treats or prevents disease in all and has no adverse effect. However, it is very unlikely that a medication is effective and safe in all patients. Therefore, when a physician determines the dose of a drug, it is always a compromise between "not www.ijpsonline.com of human beings throughout the world. We all are 99.9% similar as far as the genome is concerned 1, 28 . The remaining 0.1% of the genome leads to inter-individual differences in disease proneness and in drug response. Recently, the role of genetics has been evaluated in drug receptors, such as the β 2 -adrenoceptor, and drug transporters like the Multi-Drug Resistance gene (MDR1). The genetic variations of these and other drugmetabolizing enzymes or drug targets were highlighted when adverse drug reactions were observed in the individuals of the same families [29] [30] [31] [32] .
effort to identify SNPs that will be useful for identifying patients who are at high risk to experience adverse drug reactions or to determine the best therapeutic approach for a given patient. 38, 40 In future, SNPs will play a major role in establishing a genotype related to drug response.
With the advent of pharmacogenetics, now we are at a stage where we can develop a patient risk profile. The ability to predict inter-individual differences in drug efficacy or toxicity will thus be a realistic scenario for the future. Thus, genotyping procedures will play an important role in deciding therapeutic course. This is The most common form of DNA variation in the human already a reality in few well-documented cases 10 genome is the Single Nucleotide Polymorphism (SNP) 33, 34 . SNP is a result of a mutation in which a single nucleotide
GENETIC VARIABILITY IN
is substituted by another nucleotide at a given position.
PHARMACOKINETICS (PK) AND
SNPs occur once every 300-3,000 base-pairs if one
PHARMACODYNAMICS (PD)
compares the genomes of two unrelated individuals 35, 36 . On an average it can be said that one SNP occurs in the
The in vivo response to drug treatment is a complex and sequence of 1000 base-pairs. Thus in the entire genome highly dynamic process, which involves multiple factors. the estimate of the SNPs would be around 3.2 million in As many as 50 proteins, e.g. carrier proteins, transporters, 3.2 billion nucleotides. SNPs are responsible for most of metabolizing enzymes, receptors and their signal the inherited variations. The focus is especially on transduction components take part in pharmacodynamic medically important SNPs/traits that are related to the response to a drug. Many genes coding for these proteins predisposition of the individuals to certain diseases and contain polymorphisms that alter the activity or the level differential drug response 37 .
of expression of the encoded proteins. Thus, the response of a given drug in an individual reflects the Pharmacogenetics focuses on SNPs for the simple and interaction of multiple variable genetic factors that cause practical reason that they are both the most common and important variations in drug metabolism, distribution and the most technically accessible class of genetic variants.
action on its target 10 . For clinical correlation studies in relatively small populations, SNPs that occur at frequencies of greater Polymorphism in drug disposition -metabolism: than 10% are most likely to be useful, but rare SNPs with Of all the different processes involved in the disposition strong selection component and a more marked effect on of the drug in our body, metabolism is a major pathway phenotype are also equally important. Once a large for the elimination of drugs (Table 3) 31 . The extent of number of these SNPs and their frequencies in different polymorphism in the genes encoding enzymes that populations are known, they can be used to predict an metabolize drugs and other xenobiotics is more compared individual's genetic "fingerprint" with the probable drug to other genes. Drug response is better correlated with .
response. High-density maps of SNPs may allow using polymorphism in these genes encoding enzymes. Hence these SNPs as markers of drug responses even if the it is important to study the genes responsible for drug target remains unknown. This will provide a "drug metabolism. Several common genetic polymorphisms had response profile" associated with contributions from been identified on a phenotypic basis prior to the multiple genes 10, 38, 39 . Indeed, there is a rapidly growing characterization of relevant genes. The DNA samples www.ijpsonline.com from individuals of known phenotype after sequence often resulting in altered activity or complete absence of analysis, led to the identification of the polymorphisms enzyme protein. Analysis of functional significance has responsible for the phenotype, and the development of been facilitated by the fact that well-established systems reliable genotyping assays based mainly on the for expression of CYP are available together with robust polymerase chain reaction 10 . assays for enzyme activity. Yet the complete understanding of all the aspects has not been achieved. Polymorphism in drug metabolizing enzymes (DMEs)
Today it is possible to genotype an individual for a range have relatively clear phenotypes, hence genotyping them of CYP polymorphisms and based on the metabolic represents an area of importance in clinical medicine 41, 42 .
capability of these enzymes, individuals are classified as Liver is the main organ for drug metabolism. Liver extensive metabolizers (EMs) or poor metabolizers (PMs) metabolizing enzymes are mainly found in the for the given CYP. This information is of utility in endoplasmic reticulum of hepatocytes. As a result of predicting the metabolic capacity of an individual for a genetic polymorphism these enzymes exhibit distinct particular drugs metabolism by this CYP 47 phenotypes. Poor metabolism maybe the result of a codominant autosomal trait due to deletions, null or CYP2D6 comprises only of 1-2% of the total liver drug inactivating mutations in drug metabolizing enzymes metabolizing enzymes, but is involved in the metabolism giving rise to accumulation of the drug. Gene duplication, of more than 30% drugs (Table 4) 48,49 . At least 16 resulting in autosomal dominant trait, gives rise to ultradifferent genetic variations including point mutations rapid drug metabolism that result in reduced drug resulting in early stop codon or amino acid substitution, levels 43 . Liver metabolizing enzymes can be classified microsatellite nucleotide repeats, and gene amplifications into two groups: Phase I and phase II drug metabolizing or deletions are the causes of differences in the enzymatic activity of CYP2D6 resulting in either complete deficiency to ultra-rapid metabolism.
Polymorphism in drug metabolizing enzymes
The CYP2D6 poor-hydroxylator phenotype, the so-called The major modification that takes place by the Phase I sparteine-debrisoquine allele, is caused by homozygous enzymes is the change in the functional group, through inheritance of inactivating alleles. The frequency of this hydrolysis, oxidation and reduction. Phase I metabolism is trait varies extensively among ethnic groups, ranging from mostly carried out by the monooxgenase heme-thiolate 6% in Black Africans to 51% in Asians (Table 5) 13,50
protein superfamily, referred to as Cytochrome P450 Consequently, clinical responses to standard doses of (CYP). As CYP plays a very vital role in drug drugs metabolized by CYP2D6, such as haloperidol, metabolism, researchers were prompted to undertake a chlorpromazine, codeine and antiarrhythmics, vary from detail search for polymorphism in the human CYP genes.
increased risk of ADRs at recommended doses in poor The polymorphism of the major CYP that contribute to metabolizers, to therapeutic failure in ultra-rapid metabolism of drugs and other xenobiotics has been metabolizers 10, 51 . studied 44 . They are likely to increase incidence of adverse effects or non-response to a wide variety of CYP2C9 metabolizes a number of commonly prescribed drugs that include antidepressants, amphetamines, many drugs such as S-warfarin, phenytoin, tolbutamide and a .
enzymes.
Phase I:
. β-adrenoceptor antagonists 45 . Approximately 80 different range of nonsteroidal anti-inflammatory drugs (Table 4) 49,52
. forms of CYP have been characterized in human, each CYP2C9 which metabolizes the active enantiomer, Sof which has distinct catalytic specificity and unique warfarin in the warfarin therapy is associated with regulation 46 . Because of this diversity, the high frequency hemorrhagic complications. This analysis was based on of CYP genetic variations may be explained by their Caucasian population, studied retrospectively within a redundant or dispensable nature. In human, the major system of protocol-driven anticoagulation management. CYP enzymes responsible for the metabolism of widely
The two most common variant alleles are CYP2C9*2 prescribed drugs are CYP3A4, CYP2D6, CYP2C19, (R144C) and CYP2C9*3 (I359L) and, among northern CYP2C9, CYP1A1/2, CYP2B6, CYP2E1 and CYP2C8
31
.
Europeans, over 30% of the population has one or two of Among these, CYP2D6, CYP2C9, CYP2C19 are highly these alleles, with the overall allele frequency of polymorphic and responsible for most of the ADRs and CYP2C9*2 approximately 0.10 compared with 0.08 for inefficacy 10, 46 . CYP2C9*3 [53] [54] [55] . The distribution of CYP2C9 alleles varies Many of these polymorphisms are functionally significant, with ethnicity, but the overall frequency of variant alleles (CYP2C9*2 and CYP2C9*3) seems to be ~30% in the general population 56-59 .
CYP3A4 is involved in the metabolism of >50% of all the drugs prescribed today (see Table 4 ) 49,51 . The interindividual differences in the pharmacokinetics of these drugs is thought to be related to variation in CYP3A4 enzyme activity [60] [61] [62] . The variation may be caused by age and disease-related differences, by drugs inducing or repressing transcription/translation, or by genetic polymorphisms. Although the CYP3A4 gene was initially thought not to be very polymorphic, recent reports have described three genetic variants of this gene: CYP3A4*1B, CYP3A4*2, and CYP3A4*3 63 . The allelic frequency for the CYP3A4*1B allele, which contains an A290G substitution in the promoter region of CYP3A4 was found to be more than 54% in African Americans whereas in American and European Caucasians it was reported to be 4-5%. This mutation was not found in Chinese and Japanese Americans 64-67 .
CYP2C19 metabolizes (S)-mephenytoin and other substrates (Table 4) 49 . CYP2C19 contains several inactivating mutations, whose frequencies vary among ethnic populations 13 . Variant alleles from CYP2C19*2 to CYP2C19*8 that are responsible for the PM phenotype have been identified. Variations have been observed both at the phenotypic as well as genotypic levels and it represents wide inter-ethnic differences. For example, polymorphism of CYP2C19 cause differences in cure rate of ulcers caused by Helicobacter pylori ( fig. 1) with omeprazole 68 . Five-fold differences have been observed in PMs compared to EMs in the metabolism of the Proton Pump Inhibitors (PPIs) like omeprazole, lansoprazole and pantoprazole. Such polymorphism results in resistance to treatment at a standard dose regimen in nearly 20% of European Caucasians, and in an even higher percentage and sulfonamide-induced hypersensitivity reactions were observed in some ethnic groups perhaps due to the accumulation of drugs. The question is whether the adverse effects are really due to higher concentration of the drugs in slow acetylators ( fig. 2 , Table 6) 31,71,72 .
We have earlier seen that extensive metabolizers show poor efficacy, as in case of CYP2C19 genotype and cure rate of ulcers ( fig. 1) 68 . Consequently, the question is .
Polymorphism in drug metabolizing enzymesPhase II:
Phase II conjugation of drugs can occur alone or after phase I metabolism. In order to enhance drug excretion in urine or bile, phase II enzymes link large polar moieties to drug molecules thus rendering drugs water soluble ready for excretion. Several of these proteins have an important role in deciding drug response, such as uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1), N-acetyl transferase 2 (NAT2) and thiopurine S-methyltransferase (TMPT).
UGT1A1 detoxifies various lipophilic chemicals and endogenous substances including bilirubin. This gene contains polymorphism in a promoter region, which alters the level of expression of the encoded enzyme, resulting in a wide variation of drug metabolism 70 . The homozygous mutation in inactivated NAT2 results in a slow-inactivator phenotype. This phenotype is responsible for increased dose-dependent toxicity due to the accumulation of drugs such as in hydralazine-induced lupus, isoniazid-induced neuropathies, and sulfonamideinduced hypersensitivity reactions in some ethnic groups potentially fatal hematopoietic toxicity in some patients 73 .
40
The cited examples of both the phase I as well as phase
20
II enzymes lead us to conclusion that with the help of 0 pharmacogenetics, we can predict and classify individuals for their metabolic capabilities. However, there are a few important questions yet to be answered. As discussed earlier in the case of NAT2, adverse effects such as hydralazine-induced lupus, isoniazid-induced neuropathies, www.ijpsonline.com whether the poor/non-responder phenotype is due to lower concentration of drug in extensive metabolizer. The hypothesis ( fig. 3 ) based on phenotype-genotype data is yet to be carefully scrutinized before its implication can be translated into clinical practice.
PHARMACOGENETICS IN CLINICS REALITY TEST
For application of pharmacogenetics in clinic we need good correlation of genotyping test with therapeutic
The example of the CYP2D6 polymorphism again provides incontrovertible clinical data for these concepts. The majority of patients (~90%) require 75-150 mg/day of nortriptyline to reach a "therapeutic" plasma steady-state concentration of 200-600 nmol/l (50-150 µg/l), but poor metabolizer individuals need only 10-20 mg/day, to reach the same levels. Ultra-rapid metabolizers on the other extreme may require 300-500 mg or even >500 mg per day to reach the same plasma concentration 74 . Without knowing about the genotype or phenotype of the patient, poor metabolizers will be overdosed and be at high risk outcome. In some cases, as discussed earlier, we have of drug toxicity, whereas ultra rapid metabolizers will be good correlation between two and for others we need to under-dosed and will show inefficacy. Clinical await data from clinics which assure us that positive and observations have repeatedly confirmed these predictions. negative predictive values of such tests are close to 90%.
Hence it can be concluded that it depends much on the For establishing phenotype-genotype correlation, one drug in question. Another example is where the efficacy requires a vast data set, preferably large prospective depends on the active metabolite and not the drug (e.g., studies. Thus before realizing the utility of morphine from codeine and with time will find its rightful place in many more.
At present, phenotyping test methods are established which allow one to classify patients as PMs or EMs, but these require the administration of a specific marker drug or test drug, collection of urine, blood, or saliva for analysis of drug and metabolite concentrations. Moreover, these tests are time consuming, expensive and subject to drug-drug interactions or other influences. Genotyping tests have the advantage of having to be done only once in a lifetime and provides unequivocal genetic information. However, at times phenotype may deviate from genotype for a simple reason that phenotype is manifestation of an enzyme or protein which itself can be subjected to is also influenced by other xenobiotics in the system.
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Prediction is that with better understanding of correlation between phenotype and genotype, the trend will develop for genotyping as test of predictive of phenotype. www.ijpsonline.com inefficacy. However, it has been seen that drug metabolism and drug metabolizing enzymes are critical and perhaps sole determinant of drug response, at least in few well-established cases. In such cases the predictive values of the tests is very high in acceptable range (Table 7) 73 . The low predictive values in some cases can be attributed to the fact that metabolism is a multi-step process involving many factors which also have to be understood and incorporated in consideration to achieve better predictive values 76 .
of antidepressants 78 . Another important aspect of pharmacogenetics is the realization that all pharmacogenetic variations occur with different frequencies among sub-populations of different ethnic or racial origin. For instance, striking ethnic differences exist in the frequency of slow acetylators of isoniazid due to mutations of NAT2, in poor metabolizers of warfarin due to mutations of CYP2C9, omeprazole due to polymorphism of CYP2C19, and of ultra-rapid metabolizers due to duplication of CYP2D6 gene 29, 31, 79, 80 . Some of the mutations of these genes have a very rare Pharmacogenetics and genomics in general have ethical, occurrence in other ethnic populations. legal, financial and behavioral aspects that have not been analyzed. In addition, genotyping technology platforms Pharmacogenetics will help to tailor the drug dosage are relatively new and their ruggedness and reliability according to the individual genotype. It will help in will improve with time. Therefore, the promise of minimizing the adverse drug reactions and will reduce the improved health care through personalized drug cases of inefficacies. People will be saved from the treatment remains a realistic scenario in many areas of unnecessary exposure of drugs and their relative side effects. In future, individual will carry a genetic profile and the physician will demand for such profiles before
CONCLUSION
prescribing the medication 81 .
Pharmacogenetics has revolutionized the way in which systems 31 . Genotyping and phenotyping tests to predict ) .
